Antibody formulation for the gastrointestinal tract

点击翻译按钮获取中文摘要

Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. Thisproject proposes to develop antibody formulations appropriate for application in the GI tract. The developmentof a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.